Last reviewed · How we verify
NCT04324710
Gene Expression of Endocannabinoid System in Episodic and Chronic Migraine Patients
trial in Chronic Migraine in 75 participants. Completed in 31 December 2019.
31 December 2019
Quick facts
| Lead sponsor | IRCCS National Neurological Institute "C. Mondino" Foundation |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 75 |
| Start date | 12 December 2017 |
| Primary completion | 31 December 2019 |
| Estimated completion | 31 December 2019 |
| Sites | 1 location across Italy |
Conditions studied
- Chronic Migraine — all drugs for Chronic Migraine →
Sponsor
IRCCS National Neurological Institute "C. Mondino" Foundation
Who can join
18 and older, any sex, with Chronic Migraine. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Preclinical and clinical evidence suggests a role for the dysregulation of endocannabinoid system (ES) in migraine pain, particularly in subjects with chronic migraine. The gene expression of ES components were assayed in peripheral blood mononuclear cells (PBMCs) of patients with episodic migraine (EM), chronic migraine with medication overuse (CM-MO) and age-matched healthy controls (CT). It was evaluated the protein expression of cannabinoid receptors (CB) 1 and 2 as well as DNA methylation changes in genes involved in ES components.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04324710
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Chronic Migraine
Currently open trials in the same condition.
- NCT06974617 — Sphenopalatine Block Versus BOTOX in Management of Chronic Migraine · NA · recruiting
- NCT06684249 — Efficacy of Nerve Block Versus Botox in Chronic Migraine Management · NA · recruiting
- NCT05337033 — Cannabis for Chronic Headaches in Adolescents: the CAN-CHA Trial · Phase 2 · recruiting
- NCT06625060 — A Study to Evaluate IPN10200 Safety and Efficacy in the Prevention of Episodic or Chronic Migraine in Adults · Phase 2 · recruiting
- NCT06450444 — The RECLAIM Study. · NA · recruiting
Other IRCCS National Neurological Institute "C. Mondino" Foundation trials
Trials by the same sponsor.
- NCT06820411 — A Pilot Study to Assess Optimal Prevention and Outcome Improvement in Young Ischemic Stroke · NA · active not recruiting
- NCT06983119 — Case-Finding for Neurocognitive Disorders in Pavia · NA · recruiting
- NCT06453863 — Effects of Biofeedback Footwear in Parkinson's Disease: Assessment of Functional Motor Abilities and Locomotion · NA · not yet recruiting
- NCT06715436 — Multiple Sclerosis and the Effects of Ketogenic Diet Therapy · NA · recruiting
- NCT07442916 — Non-Invasive Brain Stimulation as Add-on Treatment in Chronic Migraine With Medication Overuse · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04324710 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by IRCCS National Neurological Institute "C. Mondino" Foundation
- Last refreshed: 27 March 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04324710.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing